Enisamium Inhibits SARS-CoV-2 RNA Synthesis.
MetadataShow full item record
Elli, S., Bojkova, D., Bechtel, M., Vial, T., Boltz, D., Muzzio, M., Peng, X., et al. (2021). Enisamium Inhibits SARS-CoV-2 RNA Synthesis.. Biomedicines, 9 (9) https://doi.org/10.3390/biomedicines9091254
Pandemic SARS-CoV-2 causes a mild to severe respiratory disease called coronavirus disease 2019 (COVID-19). While control of the SARS-CoV-2 spread partly depends on vaccine-induced or naturally acquired protective herd immunity, antiviral strategies are still needed to manage COVID-19. Enisamium is an inhibitor of influenza A and B viruses in cell culture and clinically approved in countries of the Commonwealth of Independent States. In vitro, enisamium acts through metabolite VR17-04 and inhibits the activity of the influenza A virus RNA polymerase. Here we show that enisamium can inhibit coronavirus infections in NHBE and Caco-2 cells, and the activity of the SARS-CoV-2 RNA polymerase in vitro. Docking and molecular dynamics simulations provide insight into the mechanism of action and indicate that enisamium metabolite VR17-04 prevents GTP and UTP incorporation. Overall, these results suggest that enisamium is an inhibitor of SARS-CoV-2 RNA synthesis in vitro.
Molecular dynamics simulation, RNA polymerase, Covid-19, Sars-cov-2, Fav00a, Amizon
ZonMw (10430 01 201 0018)
Wellcome Trust (206579/Z/17/Z)
External DOI: https://doi.org/10.3390/biomedicines9091254
This record's URL: https://www.repository.cam.ac.uk/handle/1810/330091
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/